Drugs / MASL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT04188665 | Jan 2021 → Dec 2024 | head and neck squamous cell carcinoma | Rowan University | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MASL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04188665 ↗ |
| Action | Inhibit | “Maackia amurensis seed lectin (MASL) can target the PDPN receptor to inhibit OSCC cell migration and viability.” PMID 40681758 ↗ Jul 2025 |
| Route | Oral | “a single 100 mg oral dose of MASL” PMID 40681758 ↗ Jul 2025 |
| Target | PDPN | “antibodies and Maackia amurensis seed lectin (MASL) can target the PDPN receptor” PMID 40681758 ↗ Jul 2025 |